Over the past four decades, HIV research has saved tens of millions of lives through discoveries in HIV treatment and prevention, with the US federal government playing a foundational role in that success. Unprecedented assaults on science and research and the systematic dismantling of federal institutions over the past months risk those accomplishments. These unparalleled budget cuts and project terminations will set the HIV/AIDS response back years, if not decades.

It’s not too late to change that! The commitment and actions of the scientific and advocacy community have been successful in reversing some of these funding decisions and we need to keep up the pressure.

Join us on September 16 starting at 11:00 ET as scientists, researchers, and advocates from around the world describe what has been achieved through decades of federal investments and what we stand to lose. Don’t miss the opportunity to come together in community as we share insights, answer questions, and inspire action.

Join the UNITED! Movement and AVAC to learn more about the future of HIV prevention and what this means for young people. The webinar will cover:

• Prevention options currently available
• Long-acting PrEP products, including those currently available, available soon, and in the pipeline
• An update on the introduction of six month lenacapavir for PrEP
• Advocacy priorities for long-acting PrEP research and rollout, with a focus on what these mean for youth
• Experiences from youth advocates involved with PrEP introduction and rollout

The session will also include time for Q&A with speakers.

Join an engaging session on the Dual Prevention Pill (DPP), featuring Kate Segal (AVAC), Barbara Friedland (Population Council), and Wawira Nyagah (AVAC). Speakers will highlight the product pipeline, the regulatory pathway, and the implementation agenda ahead—followed by a panel discussion with leading experts driving progress in MPTs.

This webinar will provide participants with scientific, policy, funding and community highlights from IAS 2025, the 13th IAS Conference on HIV Science, held in Kigali, Rwanda, in July. Attendees will gain a clearer understanding of the latest trends and emerging priorities in the global HIV response and hear reflections from stakeholders, including community voices.

Moderators

• Kenneth Ngure, School of Public Health, Jomo Kenyatta University of Agriculture and Technology and IAS — The International AIDS Society, Kenya
• Susan Shumba, Young Advocates for Inclusion Network and IAS — The International AIDS Society, Zimbabwe

Speakers

• Alexandra Calmy, Geneva University Hospitals (HUG) and IAS, Switzerland
• Gaston Devisich, Fundación Huésped, Argentina
• Doreen Moraa Moracha, Kenya

This 60-minute webinar is intended for communities, providers, policy makers and advocates for PrEP, HIV prevention and HIV testing. We will provide an overview of the key takeaways and new guidance from newly released Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis.

Thursday 28 August 2025 at 13:00 – 14:00 Geneva-time

Times in your location: 7:00 EDT / 12:00 WAT / 13:00 CEST / 13:00 SAST / 14:00 EEST / 16:30 IST / 18:00 ICT / 19:00 PHST

After registering, you will receive a confirmation email containing information about joining the webinar.

This is the first webinar in a three-part series: 

• Part 2 on 4 September 2025 focus on HIV testing (in partnership with PSI)
• Part 3 will focus on e-training for PrEP providers (in partnership with Jhpiego)

Further details about these webinars will be shared soon!

Join the International Community of Women Living with HIV Eastern Africa (ICWEA) to discuss the dapivirine vaginal ring, lenacapavir, and cabotegravir. Moderated by Lillian Mworeko and Dr. Lilian Benjamain Mwakyosi, speakers include:

• Michelle Rodolph, WHO
• Shannon Kowalski, Global Fund
• Leonard Solai, Population Council
• Yvette Raphael, Advocates for the Prevention of HIV in Africa
• Beryl Abade, youth champion and PrEP advocate

We are excited to invite you to our next TOWN HALL 📣 happening on Tuesday, August 12th at 10 AM EST!

We will be launching two critical resources:

• 📊 Market Assessment Report
• 📈 Key Population Long-Acting PrEP Demand Forecast

Gain insights from leading voices driving innovation in HIV prevention:

• ✨ Micheal Ighodaro – GBGMC
• ✨ Matt Hamilton – Avenir Health
• ✨ Catherine Verde-Hashim – AVAC

Together, we’ll explore what’s next for long-acting PrEP access, readiness, and demand among key populations globally.

👉 Click the registration link to register now!

Approved in July, lenacapavir for PrEP has tremendous potential to increase access and engagement in the United States, reaching individuals who have been unable to embrace PrEP in its previous formulations. The Choice Agenda and the HIV BLUPrInt team for a deep dive into rolling out lenacapavir (Yeztugo) in the US. Speakers summarized lessons, previewed existing resources, and called for expanded research and practice models that use lenacapavir as a lever to increase HIV prevention access, empowerment, and reach.

Recording / Slides / Resources

This is an ongoing series which occurs on the first Monday of alternating months and moderated by Drs. Patrick Sullivan (Emory Center for AIDS Research) and Kenneth Mayer (Harvard University Center for AIDS Research).

In August, AVAC Executive Director Mitchell Warren presented. Watch the presentation below. Download his slides.